Stiolto Respimat (Tiotropium Br/Olodaterol HCl) Patent Expiration, LOE Window & CMS Spending
Stiolto Respimat (Tiotropium Br/Olodaterol HCl) by Boehringer Ingelheim: FDA Orange Book core substance LOE 2027-01-19 (last listed 2028-09-13), 0 AB generics, $517.5M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Boehringer Ingelheim |
| FDA Application & Pathway | N206756 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2027-01-19 |
| Last Listed Patent or Exclusivity Date | 2028-09-13 |
| Orange Book Patents (*PED Extensions) | 3 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $517.5M |
| 2024 Medicare Part D Spend | $448.6M |
| 2024 Medicaid Spend | $68.9M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.